Loading...
Market
Story
Novavax, Sanofi Sign Multibillion-Dollar Deal for COVID-19 and Flu Vaccines
May 10, 2024, 07:34 AM
Novavax and Sanofi have entered into a multibillion-dollar licensing agreement to co-commercialize a COVID-19 vaccine and to develop novel combination vaccines for COVID-19 and influenza. The deal also includes Sanofi taking an equity stake in Novavax. This collaboration aims to enhance vaccine availability and efficacy against these respiratory diseases.
View original story
Similar markets
Novavax outperforms Sanofi • 50%
Sanofi outperforms Novavax • 50%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%